Biomedicine and Pharmacotherapy Submission Process

Before upload, run a Biomedicine and Pharmacotherapy package check to test whether the manuscript, cover letter, figures, methods, ethics statements, data availability statement, Review Proposal file if relevant, and suggested reviewers all point to the same pharmacotherapy story.

For Biomedicine & Pharmacotherapy, the process record should make the therapeutic logic easy to inspect. Editors and reviewers need to see what the intervention is, what mechanism is claimed, what disease or pharmacological context matters, and whether the evidence supports the level of therapeutic language used in the title, abstract, conclusion, and cover letter.

Use this checklist before the corresponding author starts the online record.

The strongest packages are internally consistent. The abstract, figures, methods, cover letter, ethics statement, and supplementary information should all support the same level of pharmacotherapy claim. If the conclusion says "therapeutic candidate" but the package only shows cell viability and pathway markers, the process becomes fragile before peer review.

Elsevier's public support documentation explains that the submission is not complete until the author views and approves the built PDF. For Biomedicine & Pharmacotherapy, that final preview should be treated as an editor simulation.

Do not treat PDF approval as a formality. This is the last moment to catch missing figures, broken supplementary-file labels, incomplete declarations, or a cover letter that does not match the manuscript.

Use these ranges for planning, not promises. Official Elsevier and journal pages control the actual process. For first decision planning, use 4 to 10 weeks after completed PDF approval, with any edge case slower when ethics statements, review-proposal files, mechanism claims, in-vivo evidence, transfer context, or reviewer routing are incomplete.

The main timeline trap is author-side incompletion. If the PDF is not approved, or a review article lacks the separate Review Proposal file, the manuscript is not truly moving through the scientific process yet.

Initial Quality Check is the handleability stage. For Biomedicine & Pharmacotherapy, it includes authorship and affiliation metadata, CRediT roles, COI or conflict-of-interest statement, funding disclosure, ethics statement for animal or human work, informed consent where relevant, plagiarism screening readiness, reporting checklist completeness where applicable, data availability statement, AI-use declaration, file designations, supplementary information, suggested reviewers, Review Proposal file for reviews, and Editorial Manager PDF approval.

This stage should not be used to discover whether the paper's therapeutic claim is overbuilt. Administrative readiness and claim readiness should already align. If the manuscript makes a treatment claim, the methods and main figures should support the model, dose, comparator, mechanism, toxicity or safety, and translational context at the level the title and abstract imply.

The cleanest Biomedicine & Pharmacotherapy package has one obvious spine:

• the title and abstract state the pharmacotherapy contribution
• the first figures show mechanism and evidence depth
• the methods support disease or therapeutic context
• ethics, data, and reporting statements match the study design
• the cover letter explains journal fit without overselling readiness
• the generated PDF presents the complete package cleanly

Editorial triage asks whether the manuscript belongs in a multidisciplinary pharmacotherapy journal and whether it is ready for reviewer time. The ScienceDirect journal page describes a broad clinical/basic medicine and pharmacology scope, including cancer, nutriceutics, neurodegenerative, cardiac, and infectious diseases. That breadth does not mean every biomedical mechanism paper fits.

Strong triage signals:

• abstract names the intervention, mechanism, disease context, and therapeutic implication
• main figures include mechanism plus functional or translational evidence
• in-vivo, patient-derived, organoid, pharmacokinetic, toxicity, or comparator-drug logic is proportionate to the claim
• ethics and consent language is specific
• data availability and supplementary methods are navigable
• cover letter explains why the work is pharmacotherapy rather than pure biology, chemistry, or natural-product screening
• review articles include the required Review Proposal file with relevance, originality, outline, references, and expertise

Weak triage signals:

• the result is a descriptive activity report without mechanism
• the therapeutic language outruns in-vitro or computational evidence
• the manuscript is natural-product pharmacology better suited to Phytomedicine
• the paper is broad pharmacology better suited to Pharmacological Research or European Journal of Pharmacology
• ethics, data, consent, or reporting artifacts are vague
• the PDF preview makes the evidence package hard to inspect

In our pre-submission review work with Biomedicine & Pharmacotherapy and adjacent pharmacology manuscripts, we read the process package as one record: title, abstract, figure order, methods, animal or human ethics statements, data availability statement, cover letter, supplementary files, Review Proposal file if relevant, reviewer suggestions, and the Editorial Manager PDF. Manusights internal analysis treats the leading specific failure pattern as therapeutic language without proportional pharmacotherapy evidence.

Evidence basis: Of the 50+ pharmacology, natural-product, oncology-mechanism, inflammation, neurodegeneration, and translational biomedicine manuscripts our team reviewed or analyzed for this journal family, the fragile submissions are usually not empty. Manusights review data shows a recurring process gap: authors upload activity data, pathway markers, or docking results, but the Editorial Manager record does not prove enough mechanism, in-vivo or translational support, comparator logic, and ethics/data completeness for a pharmacotherapy journal. In practice, that means the PDF looks technically complete while the pharmacotherapy case is still underbuilt.

Source limitation: Elsevier and ScienceDirect pages define the official submission mechanics, guide for authors, Review Proposal file requirement, PDF approval step, and publisher policies. They do not publish private manuscript-level desk-screen notes. The analysis below combines official-source facts with Manusights submission analysis. Editors specifically screen whether the abstract, figures, methods, ethics package, and cover letter make one pharmacotherapy argument. That is why this page exists: it translates the official process into a package-readiness check before you submit or pay for another editing pass.

• Biomedicine and Pharmacotherapy pattern 1: the abstract promises therapy, but the figures show screening. The abstract and conclusion imply treatment relevance, while the main figures mostly show cell viability, marker expression, docking, or descriptive activity. The editor has to infer pharmacotherapy consequence.

Check whether your Biomedicine and Pharmacotherapy therapeutic claim is supported →.

• Biomedicine and Pharmacotherapy pattern 2: mechanism is named but not tested. The manuscript says a pathway, receptor, inflammatory axis, apoptosis route, or oxidative-stress mechanism is involved, but the methods and figure sequence do not prove causality at the level claimed.

Check whether your Biomedicine and Pharmacotherapy mechanism is testable →.

• Biomedicine and Pharmacotherapy pattern 3: translational evidence is missing from the main record. The supplementary information may contain animal, organoid, pharmacokinetic, toxicity, comparator, or patient-derived evidence, but the PDF preview and main manuscript do not make that evidence easy for editors to inspect.

Check whether your Biomedicine and Pharmacotherapy translational bridge is visible →.

• Biomedicine and Pharmacotherapy pattern 4: review submissions miss the proposal layer. Review authors upload a manuscript and cover letter but do not provide the separate Review Proposal file with readership relevance, originality, timeliness, outline, key references, and author expertise.

This guide tells you what the Biomedicine & Pharmacotherapy process tests before and during review; the review tells you whether your package passes that read before the Editorial Manager record hardens. Paid Manusights reviews include the 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Manuscripts that clear editor triage move to external peer review. For author planning, treat the process as Elsevier editor-led, single-blind peer review. It is not transparent peer review or portable peer review by default.

Reviewer routing can slow when:

• the manuscript sits between molecular biology, pharmacology, toxicology, oncology, natural-products, and disease-specialty audiences
• the mechanism claim depends on evidence outside the main figures
• the in-vivo or translational bridge is not clear enough for a reviewer to judge
• suggested reviewers cover only the biology lane and not pharmacotherapy
• ethics, reporting checklist, data availability, AI-use, or consent statements need clarification
• a review article lacks the separate proposal context

The useful reviewer strategy is to make the manuscript easy to route. Name the pharmacology lane, disease context, intervention type, and mechanism honestly. Do not make the paper look broader by obscuring who should review it.

The final decision reflects editor synthesis of fit, reviewer reports, evidence depth, ethics and declaration readiness, revision feasibility, and journal scope. A rejection or transfer can mean the paper is scientifically interesting but not yet framed or evidenced as pharmacotherapy.

Do not treat revision as a prose-only task. In this journal family, revision often has to recalibrate the therapeutic claim and make the mechanism, model, ethics, and data package easier to inspect.

This page is a process guide, not official Elsevier guidance. Elsevier and ScienceDirect control the guide for authors, current Editorial Manager workflow, Review Proposal file requirement, PDF approval process, editorial policies, and production requirements. Manusights adds the author-side process layer: whether the submitted package makes pharmacotherapy contribution, mechanism, translational support, ethics/data readiness, review-proposal completeness, and reviewer routing visible before editor triage.